Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Tacrolimus

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01283295Recruiting

Immune Monitoring and Assay Development in Organ Transplant Recipients

NCT00717678Phase 3Completed

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

NCT00720408Phase 3Completed

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

Showing all 3 trials

Research Network

Common Treatments

  • Tacrolimus2
  • Mycophenolate Mofetil2

Active Sponsors

  • Astellas Pharma Taiwan, Inc.2
  • Astellas Pharma Inc2
  • Emory University1

Top Investigators

Related Conditions

  • Host Vs Graft Reaction2
  • Liver Transplantation1
  • Kidney Transplantation1
  • Organ Transplantation1

Activity Timeline